Modulation of inflammation by chondroitin sulfate

Osteoarthritis and Cartilage

Volumn 18, Issue SUPPL. 1, 2010, Pages

  Vallieres M ^a   du Souich, P ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Atherosclerosis; Chondroitin sulfate; Immune diseases; Inflammation; Inflammatory bowel diseases; Oateoarthritis; Parkinson's and Alzheimer's diseases; Psoriasis; Review

Indexed keywords

CHONDROITIN SULFATE; CYCLOOXYGENASE 2; CYTOKINE; ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MATRIX METALLOPROTEINASE; MEMBRANE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE A2; ANTIINFLAMMATORY AGENT;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ATHEROSCLEROSIS; CARTILAGE CELL; DRUG BINDING SITE; ENTERITIS; ENZYME ACTIVATION; GENE EXPRESSION; GENE TARGETING; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATORY DISEASE; LIVER CELL; MACROPHAGE; MULTIPLE SCLEROSIS; NONHUMAN; OSTEOARTHRITIS; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; PSORIASIS; RHEUMATOID ARTHRITIS; SYNOVIUM; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY; INFLAMMATION; INFLAMMATORY BOWEL DISEASES;

ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; CHONDROITIN SULFATES; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; OSTEOARTHRITIS; PSORIASIS;

EID: 77953810573     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2010.02.017     Document Type: Article

References (70)

1. Carneiro L.A., Magalhaes J.G., Tattoli I., Philpott D.J., Travassos L.H. Nod-like proteins in inflammation and disease. J Pathol 2008, 214:136-148.
2. Cinel I., Opal S.M. Molecular biology of inflammation and sepsis: a primer. Crit Care Med 2009, 37:291-304.
3. Dumais G., Iovu M., du Souich P. Inflammatory reactions and drug response: importance of cytochrome P450 and membrane transporters. Expert Rev Clin Pharmacol 2008, 1:627-647.
4. Osterloh A., Veit A., Gessner A., Fleischer B., Breloer M. Hsp60-mediated T cell stimulation is independent of TLR4 and IL-12. Int Immunol 2008, 20:433-443.
5. Yasuda T. Cartilage destruction by matrix degradation products. Mod Rheumatol 2006, 16:197-205.
6. Jiang D., Liang J., Noble P.W. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol 2007, 23:435-461.
7. Calderwood S.K., Mambula S.S., Gray P.J. Extracellular heat shock proteins in cell signaling and immunity. Ann N Y Acad Sci 2007, 1113:28-39.
8. Ohno S., Im H.J., Knudson C.B., Knudson W. Hyaluronan oligosaccharides induce matrix metalloproteinase 13 via transcriptional activation of NF-kappaB and p38 MAP kinase in articular chondrocytes. J Biol Chem 2006, 281:17952-17960.
9. Forsyth C.B., Pulai J., Loeser R.F. Fibronectin fragments and blocking antibodies to alpha2beta1 and alpha5beta1 integrins stimulate mitogen-activated protein kinase signaling and increase collagenase 3 (matrix metalloproteinase 13) production by human articular chondrocytes. Arthritis Rheum 2002, 46:2368-2376.
10. Jiang Y., Chen G., Zheng Y., Lu L., Wu C., Zhang Y., et al. TLR4 signaling induces functional nerve growth factor receptor p75NTR on mouse dendritic cells via p38MAPK and NF-kappa B pathways. Mol Immunol 2008, 45:1557-1566.
11. Zhong J., Kyriakis J.M. Dissection of a signaling pathway by which pathogen-associated molecular patterns recruit the JNK and p38 MAPKs and trigger cytokine release. J Biol Chem 2007, 282:24246-24254.
12. Ghosh S., Hayden M.S. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 2008, 8:837-848.
13. Atreya I., Atreya R., Neurath M.F. NF-kappaB in inflammatory bowel disease. J Intern Med 2008, 263:591-596.
14. van der Woude C.J., Kleibeuker J.H., Jansen P.L., Moshage H. Chronic inflammation, apoptosis and (pre-)malignant lesions in the gastro-intestinal tract. Apoptosis 2004, 9:123-130.
15. Brown K.D., Claudio E., Siebenlist U. The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther 2008, 10:212.
16. Tsuruta D. NF-kappaB links keratinocytes and lymphocytes in the pathogenesis of psoriasis. Recent Pat Inflamm Allergy Drug Discov 2009, 3:40-48.
17. Xanthoulea S., Curfs D.M., Hofker M.H., de Winther M.P. Nuclear factor kappa B signaling in macrophage function and atherogenesis. Curr Opin Lipidol 2005, 16:536-542.
18. Granic I., Dolga A.M., Nijholt I.M., van Dijk G., Eisel U.L. Inflammation and NF-kappaB in Alzheimer's disease and diabetes. J Alzheimers Dis 2009, 16:809-821.
19. Wilms H., Zecca L., Rosenstiel P., Sievers J., Deuschl G., Lucius R. Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications. Curr Pharm Des 2007, 13:1925-1928.
20. Janssen-Heininger Y.M., Poynter M.E., Aesif S.W., Pantano C., Ather J.L., Reynaert N.L., et al. Nuclear factor kappaB, airway epithelium, and asthma: avenues for redox control. Proc Am Thorac Soc 2009, 6:249-255.
21. Matsuda N., Hattori Y. Systemic inflammatory response syndrome (SIRS): molecular pathophysiology and gene therapy. J Pharmacol Sci 2006, 101:189-198.
22. Prasad S., Ravindran J., Aggarwal B.B. NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem 2009.
23. Lleo A., Galea E., Sastre M. Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases. Cell Mol Life Sci 2007, 64:1403-1418.
24. Uwe S. Anti-inflammatory interventions of NF-kappaB signaling: potential applications and risks. Biochem Pharmacol 2008, 75:1567-1579.
25. Aleksandra Nielsen A., Nederby Nielsen J., Schmedes A., Brandslund I., Hey H. Saliva Interleukin-6 in patients with inflammatory bowel disease. Scand J Gastroenterol 2005, 40:1444-1448.
26. Nancey S., Hamzaoui N., Moussata D., Graber I., Bienvenu J., Flourie B. Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity. Dig Dis Sci 2008, 53:242-247.
27. Rashmi R., Rao K.S., Basavaraj K.H. A comprehensive review of biomarkers in psoriasis. Clin Exp Dermatol 2009, 34:658-663.
28. Ridker P.M. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev 2007, 65:253-259.
29. Crandall M.A., Corson M.A. Use of biomarkers to develop treatment strategies for atherosclerosis. Curr Treat Options Cardiovasc Med 2008, 10:304-315.
30. Chen H., O'Reilly E.J., Schwarzschild M.A., Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol 2008, 167:90-95.
31. Kaplin A., Carroll K.A., Cheng J., Allie R., Lyketsos C.G., Calabresi P., et al. IL-6 release by LPS-stimulated peripheral blood mononuclear cells as a potential biomarker in Alzheimer's disease. Int Psychogeriatr 2009, 21:413-414.
32. Turner M.R., Kiernan M.C., Leigh P.N., Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 2009, 8:94-109.
33. Heikkila K., Harris R., Lowe G., Rumley A., Yarnell J., Gallacher J., et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009, 20:15-26.
34. Schubert C., Hong S., Natarajan L., Mills P.J., Dimsdale J.E. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun 2007, 21:413-427.
35. Greenfield J.R., Campbell L.V. Relationship between inflammation, insulin resistance and type 2 diabetes: 'cause or effect'?. Curr Diabetes Rev 2006, 2:195-211.
36. Aggarwal B.B., Shishodia S., Sandur S.K., Pandey M.K., Sethi G. Inflammation and cancer: how hot is the link?. Biochem Pharmacol 2006, 72:1605-1621.
37. Kuettner K.E., Cole A.A. Cartilage degeneration in different human joints. Osteoarthritis Cartilage 2005, 13:93-103.
38. Loeser R.F., Yammani R.R., Carlson C.S., Chen H., Cole A., Im H.J., et al. Articular chondrocytes express the receptor for advanced glycation end products: potential role in osteoarthritis. Arthritis Rheum 2005, 52:2376-2385.
39. Iovu M., Dumais G., du Souich P. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage 2008, 16(Suppl 3):S14-18.
40. Monfort J., Pelletier J.P., Garcia-Giralt N., Martel-Pelletier J. Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues. Ann Rheum Dis 2008, 67:735-740.
41. Fan Z., Soder S., Oehler S., Fundel K., Aigner T. Activation of interleukin-1 signaling cascades in normal and osteoarthritic articular cartilage. Am J Pathol 2007, 171:938-946.
42. Jomphe C., Gabriac M., Hale T.M., Heroux L., Trudeau L.E., Deblois D., et al. Chondroitin sulfate inhibits the nuclear translocation of nuclear factor-kappaB in interleukin-1beta-stimulated chondrocytes. Basic Clin Pharmacol Toxicol 2008, 102:59-65.
43. Harris E.N., Weigel P.H. The ligand-binding profile of HARE: hyaluronan and chondroitin sulfates A, C, and D bind to overlapping sites distinct from the sites for heparin, acetylated low-density lipoprotein, dermatan sulfate, and CS-E. Glycobiology 2008, 18:638-648.
44. Sobal G., Sinzinger H. Binding of [99mTc]chondroitin sulfate to scavenger receptors on human chondrocytes as compared to binding of oxidized [125I]LDL on human macrophages. J Recept Signal Transduct Res 2002, 22:459-470.
45. Kawashima H., Hirose M., Hirose J., Nagakubo D., Plaas A.H., Miyasaka M. Binding of a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to L-selectin, P-selectin, and CD44. J Biol Chem 2000, 275:35448-35456.
46. Suwan K., Choocheep K., Hatano S., Kongtawelert P., Kimata K., Watanabe H. Versican/PG-M assembles hyaluronan into extracellular matrix and inhibits CD44-mediated signaling toward premature senescence in embryonic fibroblasts. J Biol Chem 2009, 284:8596-8604.
47. Ajisaka K., Agawa S., Nagumo S., Kurato K., Yokoyama T., Arai K., et al. Evaluation and comparison of the antioxidative potency of various carbohydrates using different methods. J Agric Food Chem 2009, 57:3102-3107.
48. Bondeson J., Lauder S., Wainwright S., Amos N., Evans A., Hughes C., et al. Adenoviral gene transfer of the endogenous inhibitor IkappaBalpha into human osteoarthritis synovial fibroblasts demonstrates that several matrix metalloproteinases and aggrecanases are nuclear factor-kappaB-dependent. J Rheumatol 2007, 34:523-533.
49. Tas S.W., Vervoordeldonk M.J., Hajji N., May M.J., Ghosh S., Tak P.P. Local treatment with the selective IkappaB kinase beta inhibitor NEMO-binding domain peptide ameliorates synovial inflammation. Arthritis Res Ther 2006, 8. R86.
50. Omata T., Itokazu Y., Inoue N., Segawa Y. Effects of chondroitin sulfate-C on articular cartilage destruction in murine collagen-induced arthritis. Arzneimittelforschung 2000, 50:148-153.
51. Clegg D.O., Reda D.J., Harris C.L., Klein M.A., O'Dell J.R., Hooper M.M., et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006, 354:795-808.
52. Rolls A., Cahalon L., Bakalash S., Avidan H., Lider O., Schwartz M. A sulfated disaccharide derived from chondroitin sulfate proteoglycan protects against inflammation-associated neurodegeneration. FASEB J 2006, 20:547-549.
53. Bruyere O., Reginster J.Y. Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging 2007, 24:573-580.
54. Vangsness C.T., Spiker W., Erickson J. A review of evidence-based medicine for glucosamine and chondroitin sulfate use in knee osteoarthritis. Arthroscopy 2009, 25:86-94.
55. Kahan A., Uebelhart D., De Vathaire F., Delmas P.D., Reginster J.Y. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009, 60:524-533.
56. Herrero-Beaumont G., Marcos M.E., Sanchez-Pernaute O., Granados R., Ortega L., Montell E., et al. Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis. Br J Pharmacol 2008, 154:843-851.
57. Abdou A.G., Hanout H.M. Evaluation of survivin and NF-kappaB in psoriasis, an immunohistochemical study. J Cutan Pathol 2008, 35:445-451.
58. Johansen C., Flindt E., Kragballe K., Henningsen J., Westergaard M., Kristiansen K., et al. Inverse regulation of the nuclear factor-kappaB binding to the p53 and interleukin-8 kappaB response elements in lesional psoriatic skin. J Invest Dermatol 2005, 124:1284-1292.
59. Li H., Gao L., Shen Z., Li C.Y., Li K., Li M., et al. Association study of NFKB1 and SUMO4 polymorphisms in Chinese patients with psoriasis vulgaris. Arch Dermatol Res 2008, 300:425-433.
60. Lizzul P.F., Aphale A., Malaviya R., Sun Y., Masud S., Dombrovskiy V., et al. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol 2005, 124:1275-1283.
61. Verges J., Montell E., Herrero M., Perna C., Cuevas J., Perez M., et al. Clinical and histopathological improvement of psoriasis with oral chondroitin sulfate: a serendipitous finding. Dermatol Online J 2005, 11:31.
62. Hori Y., Hoshino J., Yamazaki C., Sekiguchi T., Miyauchi S., Horie K. Effects of chondroitin sulfate on colitis induced by dextran sulfate sodium in rats. Jpn J Pharmacol 2001, 85:155-160.
63. Yomogida S., Kojima Y., Tsutsumi-Ishii Y., Hua J., Sakamoto K., Nagaoka I. Glucosamine, a naturally occurring amino monosaccharide, suppresses dextran sulfate sodium-induced colitis in rats. Int J Mol Med 2008, 22:317-323.
64. Gutierrez S.H., Kuri M.R., del Castillo E.R. Cardiac role of the transcription factor NF-kappaB. Cardiovasc Hematol Disord Drug Targets 2008, 8:153-160.
65. Zhang H., Park Y., Wu J., Chen X., Lee S., Yang J., et al. Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond) 2009, 116:219-230.
66. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
67. Steinhubl S.R., Badimon J.J., Bhatt D.L., Herbert J.M., Luscher T.F. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 2007, 12:113-122.
68. Murata K. The effects of sulfated polysaccharides obtained from seaweeds on experimental atherosclerosis. J Gerontol 1962, 17:30-36.
69. Morrison L.M. Response of ischemic heart disease to chondroitin sulfate-A. J Am Geriatr Soc 1969, 17:913-923.
70. Morrison L.M., Enrick N. Coronary heart disease: reduction of death rate by chondroitin sulfate A. Angiology 1973, 24:269-287.